For Immediate Release
The Canadian Breast Cancer Network (CBCN) commends the Ontario Ministry of Health for their swift action to expand access to new metastatic breast cancer treatments in the province.
Effective October 17th, the Ontario Ministry of Health announced that Cancer Care Ontario will, for a time-limited basis, provide access to Kadcyla through the New Drug Funding Program for HER-2 positive, metastatic breast cancer patients who have initiated or completed at least two lines of HER-2 targeted therapy and who have not received Kadcyla in previous lines of therapy.
The decision to provide Ontarians living with metastatic breast cancer greater access to new treatment options is a bold step in the right direction and will have an enormous impact on people battling serious illnesses. “We are so pleased to have worked with the Ministry of Health to promote expanded access to metastatic breast cancer treatments in Ontario,” said Cathy Ammendolea, Board Chair, Canadian Breast Cancer Network. “With this decision, Ontario has demonstrated great commitment towards optimizing patient outcomes and ensuring that Ontarians living with metastatic breast cancer can quickly and affordably access the potentially life-saving treatments they need.”
Providing access to new and more effective treatments gives patients a fighting chance to live much longer and spend precious time with loved ones. The Canadian Breast Cancer Network urges all provinces and jurisdictions to follow the leadership of Ontario and ensure that essential treatments for metastatic breast cancer are added to all provincial drug formularies.
For more information, please contact CBCN at 613-230-3044 or NChari@cbcn.ca
About the Canadian Breast Cancer Network
The Canadian Breast Cancer Network is the leading survivor-directed, national network of organizations and individuals concerned about breast cancer. The Canadian Breast Cancer Network exists to voice the concerns of breast cancer patients and survivors and promote the best quality of care for all Canadians affected by breast cancer.